The Pink Elephant, Part 2: Four Cases, Four Conversations That Don't Happen Often Enough
The first session in this series laid out the data — the trials, the guideline gaps, the WHI's lasting distortion of clinical practice. This one asked a harder question: what do you actually do when the patient is sitting in front of you?
Four cases. Four distinct clinical situations. And a panel willing to disagree in real time about where the evidence ends and clinical judgment begins.
This is Part 2 of a two-part Monday Night Discussion Group series on MHT in breast cancer survivors. The February 25, 2025 session was led by Dr. Mary Jane Minkin, with Dr. Corinne Menn and Dr. Maryam Lustberg presenting, joined by Dr. Laura Esserman as a prominent discussant. Dr. Amy Comander was unable to attend.
← Part 1: A Review of the Data
What This Session Was — and Wasn't
Case-based sessions in this space can easily collapse into one of two failure modes: either the panel retreats into hedging, leaving clinicians no better equipped than before, or individual speakers wade into clinical specifics that don't hold across the variation in real patients.
This panel did neither. What emerged instead was a set of frameworks — ways of thinking about risk, symptom burden, formulation, timing, and multidisciplinary communication — that move across case types even when the cases themselves don't.
The session covered four cases spanning the full risk spectrum: a high-risk woman without a breast cancer diagnosis, a DCIS patient who stopped treatment and found her own way to pellets, a 36-year-old with triple-negative disease two years out from treatment, and a 60-year-old who completed a decade of tamoxifen after node-positive ER-positive disease and still has severe vasomotor symptoms. A fifth case was prepared but not reached.
The Frameworks That Cut Across All Four Cases
Not everyone asking for MHT actually needs systemic MHT
This came up in the first case and never fully left. Before any hormone conversation happens, the panel argued, clinicians need to do what most aren't doing: assess the actual symptom. GSM, sleep disruption, mood changes, and sexual dysfunction each have targeted treatment pathways — and many patients who arrive asking for hormones have never had those symptoms addressed at all. Dr. Menn's framing was pointed: a significant portion of these women stop wanting systemic therapy once someone actually talks to them.
"Most of these patients can't even get vaginal estrogen. If you just actually talk to them and tell them there is hope and options, half of them don't even want systemic hormone therapy anymore at that point. But the problem is, they don't even get that discussion." — Corinne Menn, MD
Formulation is not fungible.
The panel was united on this. Not all hormone therapy carries the same risk profile, and the conversation around breast cancer survivorship in particular requires distinguishing between synthetic progestins, micronized progesterone, estrogen alone, and SERM-based combinations. The case discussions returned to this repeatedly — and the differences between formulations weren't treated as minor details. They shaped the entire clinical calculus in each scenario.
Understanding recurrence risk is a prerequisite, not a formality
The panel pushed back — gently but clearly — on the idea that clinicians outside of oncology can navigate these conversations without a working understanding of recurrence risk. That means distinguishing between local recurrence, new primary risk, and late distant recurrence. It means knowing that ER-positive and triple-negative disease have fundamentally different recurrence timing curves. And it means having some familiarity with prognostic tools — Oncotype scores, MammaPrint, and pathologic response after neoadjuvant treatment — that refine those estimates in individual patients. The panel suggested that what's often called "fear of liability" is frequently a cover for not knowing oncology.
The endocrine therapy holiday is underused.
Across two of the four cases, the discussion turned to structured treatment breaks as a clinical strategy — not abandonment of adjuvant therapy, but a thoughtful, time-limited pause designed to help patients distinguish treatment side effects from other contributors to their symptom burden. The SOUL Study data, which was cited 9 months on, 3 months off, showed no loss of efficacy. The minimum washout to evaluate anything meaningfully, the panel noted, is 4 to 6 weeks — a detail many clinicians and patients don't know. Dr. Menn framed this as "the power of the pause," and described patients who are treatment-worn from diagnosis through reconstruction through chemotherapy through ovarian suppression who hit adjuvant endocrine therapy at their absolute lowest. Sometimes the clinical move is to give them breathing room.
The hardest cases are not the high-risk patients
The fourth case generated the most friction: a 60-year-old who completed a full decade of tamoxifen after node-positive, multifocal ER-positive disease, and is now severely symptomatic. The panel named the late recurrence risk honestly — ER-positive disease can recur at 15, 20, even 25 years — and then didn't stop there. Tools for refining that risk exist. Non-hormonal options have improved meaningfully. And for a patient who has done everything asked of her for a decade, the question of what her quality of life is worth deserves a real answer.
"They ring the bell at 5 years. They do the happy dance at 10 years. But the threat still weighs over them — and most patients don't fully understand what that means." — Corinne Menn, MD
A Note on Where the Consensus Is — and Isn't
The panel reached a clear agreement in some areas. Testosterone pellets, with their unregulated compounding and super-physiologic dosing, were a consistent no across all cases. The conversation for patients who've had a bilateral mastectomy for DCIS was treated as meaningfully different from the conversation for patients with invasive disease. Non-hormonal options, vaginal estrogen, and local therapies were described as the floor — not the ceiling — of what these patients should be receiving.
Where the panel didn't fully converge was around testosterone in the survivorship setting (low-dose, guideline-concordant, ISSWSH-aligned) — particularly for younger women with surgical menopause and markedly suppressed levels. Dr. Lustberg was candid about the oncology community's limited familiarity with the data. Dr. Esserman cited emerging mechanistic rationale and implications for trial design. Dr. Menn held the patient perspective. The conversation ended where the field is: promising signals, not enough data, and an urgent need to stop collecting anecdotal experience and start collecting it systematically.
Dr. Lustberg's comment near the end of the session is worth sitting with:
"This discussion is a bubble. I want to acknowledge that you will still face resistance. Plenty of oncologists — even in my own institution — would say absolutely not." — Maryam Lustberg, MD, MPH.
The cases in this session were not designed to produce algorithms. They were designed to build the clinical reasoning that makes the conversation possible at all — to reduce the distance between the 180 clinicians in this room and the millions of patients who never get the conversation anywhere.
Access the Full Recording
The full session — including all four case presentations, panel discussion, and live Q&A — is available to HERmedicine members.
Frequently Asked Questions
What is an endocrine therapy holiday?
An endocrine therapy holiday is a structured, time-limited break from adjuvant endocrine therapy — not abandonment, but a planned pause to help distinguish treatment side effects from other contributors to symptoms. SOUL Study data support a 9-months-on, 3-months-off approach with no loss of efficacy. A minimum 4–6 week washout is needed to evaluate anything meaningfully.
Is MHT an option for women with DCIS who have had a bilateral mastectomy?
The panel treated this as a meaningfully different clinical conversation from invasive breast cancer. Women with DCIS who have undergone bilateral mastectomy represent a distinct risk profile, and the MHT calculus differs substantially from that for women with a history of invasive disease. The full session addresses this case directly.
What prognostic tools help assess recurrence risk in breast cancer survivors?
Tools that refine individual recurrence estimates include Oncotype DX, MammaPrint, and pathologic response assessment after neoadjuvant treatment. Understanding what these tools measure — and what they don't — is a prerequisite for meaningful shared decision making around MHT in breast cancer survivors outside of oncology.
How should clinicians outside oncology approach MHT conversations with breast cancer survivors?
The panel's framework: establish the patient's individual recurrence risk — distinguishing local recurrence, new primary risk, and late distant recurrence — review the evidence honestly, and engage in documented shared decision making in collaboration with the oncology team. The panel noted that what's often called fear of liability is frequently insufficient oncology literacy.
About the Speakers
Mary Jane Minkin, MD - Session Moderator
Mary Jane Minkin, MD, is a Clinical Professor of Obstetrics and Gynecology at Yale School of Medicine with nearly five decades in women's health. She is a recognized authority in menopause medicine and has been a practicing clinical voice across the full arc of the evidence — from the pre-WHI era through the present. Dr. Minkin presents in Part 2 of this series.
Corinne Menn, DO, MSCP
Corinne Menn, DO MSCP, is an OB-GYN and menopause-certified practitioner whose clinical work sits at the intersection of menopause medicine and breast cancer survivorship. A 23-year breast cancer survivor and BRCA2 carrier, she brings both clinical expertise and firsthand patient experience to a topic she has spent her career working to normalize. Dr. Menn provides telehealth consultations in menopause management and survivorship, serves on the advisory board of the Young Survival Coalition, and has developed CME programming specifically for clinicians navigating MHT decisions in breast cancer survivors.
Maryam Lustberg, MD, MPH
Maryam Lustberg, MD, MPH, is Chief of Breast Oncology and Director of the Breast Center at Yale Cancer Center in New Haven, Connecticut. She serves as co-chair of symptom intervention research for Alliance Clinical Trials and is the immediate past president of MASCC, the international organization dedicated to advancing cancer supportive care. Her research focuses on the long-term sequelae of breast cancer treatment, including menopausal symptoms and survivorship outcomes. Dr. Lustberg presents in Part 2 of this series.
Laura Esserman, MD, MBA — Guest Discussant
Laura Esserman, MD, MBA, is a breast surgical oncologist and Professor of Surgery at UCSF, where she directs the Carol Franc Buck Breast Care Center. She is the principal investigator of the I-SPY trial program and a leading voice in risk-adaptive, precision approaches to breast cancer diagnosis and treatment, including active surveillance for DCIS. Dr. Esserman joined this session as a guest discussant.
